1. ORIC will present data on enozertinib at ESMO Asia Congress 2025. 2. Presentations focus on NSCLC patients with specific EGFR mutations. 3. Key oral presentations scheduled for December 5 and 6, 2025. 4. Conference call for stakeholders will happen after the presentations. 5. ORIC's pipeline includes other promising oncology candidates.